Darglitazone (previously known as CP 86325-2) is a member of the

thiazolidinedione The thiazolidinediones , abbreviated as TZD, also known as glitazones after the prototypical drug ciglitazone, are a class of heterocyclic compounds consisting of a five-membered C3NS ring. The term usually refers to a family of drugs used i ...

class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by

Pfizer Pfizer Inc. ( ) is an American Multinational corporation, multinational Pharmaceutical industry, pharmaceutical and biotechnology corporation headquartered at The Spiral (New York City), The Spiral in Manhattan, New York City. Founded in 184 ...

as a treatment of metabolic disorders such as

type 2 diabetes mellitus Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent ur ...

. Its development was terminated on November 08, 1999. Darglitazone is a thiazolidinedione, which is a class of drugs that can lower blood sugar without increasing insulin production. It's an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), a transcription factor. Darglitazone can increase the effectiveness of insulin in people with obesity and type 2 diabetes
Darglitazone is a thiazolidinedione, which is a class of drugs that can lower blood sugar without increasing insulin production.

Synthesis

References

{{PPAR modulators Abandoned drugs Oxazoles Thiazolidinediones